Furthermore, it was also confirmed by a B-ALL PDX model that TLR9 agonist monotherapy may be effective against Ph− B-ALL with C-MYC overexpression and without BAX deletion. This evidence concerns the gene BAX and acute lymphoblastic leukemia.